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Cancer cells preferentially metabolize glucose by aerobic glycolysis,
characterized by increased lactate production. This distinctive
metabolism involves expression of the embryonic M2 isozyme of
pyruvate kinase, in contrast to the M1 isozyme normally expressed
in differentiated cells, and it confers a proliferative advantage to
tumor cells. The M1 and M2 pyruvate-kinase isozymes are
expressed from a single gene through alternative splicing of a pair
of mutually exclusive exons. We measured the expression of M1
and M2 mRNA and protein isoforms in mouse tissues, tumor cell
lines, and during terminal differentiation of muscle cells, and show
that alternative splicing regulation is sufficient to account for the
levels of expressed protein isoforms. We further show that the
M1-specific exon is actively repressed in cancer-cell lines—although
someM1mRNA is expressed in cell lines derived from brain tumors
—and demonstrate that the related splicing repressors hnRNP A1
and A2, as well as the polypyrimidine-tract-binding protein PTB,
contribute to this control. Downregulation of these splicing
repressors in cancer-cell lines using shRNAs rescues M1 isoform
expression and decreases the extent of lactate production. These
findings extend the links between alternative splicing and cancer,
and begin to define some of the factors responsible for the switch
to aerobic glycolysis.
aerobic glycolysis ∣ cancer ∣ RNA splicing
Cancer cells exhibit a metabolic phenotype characterized byincreased glycolysis with lactate generation, regardless of
oxygen availability—a phenomenon termed the Warburg effect.
Recent work demonstrated that expression of the type II isoform
of the pyruvate-kinase-M gene (PKM2, referred to here as PK-M)
is a critical determinant of this metabolic phenotype, and confers
a selective proliferative advantage to tumor cells in vivo (1). This
finding adds to the growing body of evidence that alterations in
alternative prem-RNA splicing play important roles in different
aspects of cancer progression (2, 3).
Pyruvate-kinase (PK) is the enzyme that catalyzes the final step
in glycolysis, generating pyruvate and ATP from phosphoenolpyr-
uvate and ADP (4). The resulting pyruvate can be converted to
lactate or it can be incorporated into the tricarboxylic acid (TCA)
cycle to drive oxidative phosphorylation. PK is encoded by two
paralogous genes, each of which is alternatively spliced, such that
four PK isoforms are expressed in mammals. The L and R iso-
zymes, derived from the PKLR gene, show tissue-specific expres-
sion in the liver and red-blood cells, respectively. They have
different first exons, defined by tissue-specific promoters (5).
The PKM2 (PK-M) gene consists of 12 exons, of which exons
9 and 10 are alternatively spliced in a mutually exclusive fashion
to give rise to the PK-M1 and PK-M2 isoforms, respectively (6).
Exons 9 and 10 each encode a 56 amino acid variable segment
that confers distinctive properties to the regulation and activity
of PK-M1 and PK-M2 enzymes; as a result, PK-M1 is constitu-
tively active, whereas the activity of PK-M2 is allosterically regu-
lated by fructose-1,6-bisphosphate levels and interaction with
tyrosine-phosphorylated proteins (1).
The ability of PK-M2 activity to be regulated is thought to
provide a mechanism for cells to control the availability of
metabolites for anabolic processes, and to confer a proliferative
advantage during tumorigenesis (7). Despite increasing evidence
demonstrating the significance of PK-M2 isoform expression in
cancer-cell metabolism and tumorigenesis, the mechanisms gov-
erning alternative splicing of the PK-M gene are not understood.
PK-M2 is expressed in a range of cancer cells, as well as in fetal
and undifferentiated adult tissues, whereas PK-M1 is expressed
predominantly in terminally differentiated tissues (1, 8).
Alternative splicing involving pairs of mutually exclusive exons
represents only ∼2% of all alternative splicing events in human
genes (9). In terms of gene structure, the regulated exons in such
genes are often closely related in sequence—as in the case of PK-
M exons 9 and 10—indicating that they originally arose by exon
duplication (10). Well characterized examples of this alternative
splicing pattern in mammals include the tropomyosins, fibroblast
growth factor receptor 2, and α-actinin [reviewed in (11)].
Although some of the trans-acting factors involved in the recog-
nition of individual mutually exclusive exons in these genes have
been identified, it remains unclear how these pairs of exons
are coordinately regulated in a way that maintains their mutually
exclusive properties (11).
We have begun to dissect the molecular mechanisms underly-
ing PK-M2 alternative splicing regulation. Previous work impli-
cated the splicing-repressor paralogs PTB and nPTB in the
repression of exon 9 (12). In addition, other splicing repressors,
such as hnRNPA1 and hnRNPA2, and activators, such as SF2/
ASF, have been implicated in oncogenic transformation (2, 3),
and hence could potentially play a role in PK-M alternative splic-
ing. Here we characterize the expression of PK-M isoforms at the
mRNA and protein level in primary tissues and cancer-cell lines,
as well as during terminal differentiation of muscle cells in
culture. We show that hnRNPA1/A2, in addition to PTB, repress
the use of exon 9, such that knocking down expression of these
splicing repressors allows expression of PK-M1, accompanied by
a decrease in lactate production.
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Results
Relative PK-M1 and PK-M2 Expression in Tissues and Cell Lines Corre-
lates with hnRNP A1/A2 and PTB Expression. Proliferating cells and
cancer cells preferentially express PK-M2 over PK-M1 at the pro-
tein level (1, 13). To determine if the expressed protein isozymes
are a direct reflection of differences in alternative splicing—as
opposed to, e.g., being affected by mRNA stability or transla-
tional control—we measured the levels of mRNA and protein
isoforms expressed in various tissues and cell lines. Representa-
tive organs/tissues isolated from adult mice were perfused with
saline, and total protein and RNA were isolated and analyzed.
The relative expression of PK-M1 and PK-M2 protein isoforms
was organ/tissue-specific: Brain and skeletal muscle preferentially
expressed PK-M1, whereas spleen and lung expressed mainly
PK-M2, as detected by Western blotting with isoform-specific
antibodies (Fig. 1A). As previously reported (1), several human
cell lines expressed PK-M2 protein with no detectable PK-M1
(Fig. 1B). Among the cell lines tested, however, two brain-tu-
mor-derived cell lines, namely U-118MG and A-172 glioblastoma
cells, expressed detectable levels of PK-M1 protein, in addition to
PK-M2, reminiscent of the protein pattern in mouse brain, where
both isoforms are also readily detectable (cf. Fig. 1B, Fig. 1A).
To accurately measure the relative levels of PK alternatively
spliced mRNA isoforms, we simultaneously detected both
isoforms by radioactive RT-PCR with a single pair of primers cor-
responding to the flanking constitutive exons 8 and 11. Because
exons 9 and 10 are identical in length (167 nt), the resulting
cDNA amplicons were digested with restriction enzymes that
cleave either exon 9 or 10 to distinguish the two isoforms (Fig. 1C;
see also (14)). PK-M1 mRNA was the predominant isoform in
striated muscle and brain—tissues that are enriched in terminally
differentiated, nonproliferating cells. In contrast, PK-M2 mRNA
was the major isoform in lung and spleen, presumably reflecting
the abundance of proliferating cells in these organs. PK-M2
mRNA was invariably the major isoform in all cancer or trans-
formed cell lines we assayed, consistent with the previous finding
that PK-M2 expression at the protein level is strongly correlated
with, and facilitates, proliferation and tumorigenesis (1)). How-
ever, PK-M1 mRNA was readily detectable in brain-tumor-
derived cancer-cell lines, including glioblastoma (U-118MG
and A-172) and neuroblastoma (SK-N-BE) cell lines. This finding
is consistent with PK-M1 protein being detectable in U-118MG
cells and to a lesser extent in A-172 cells (Fig. 1B). In general, we
observed a strong correlation between PK-M1/M2 isoform ratios
measured at the protein and mRNA levels, in both tissues and
cell lines.
To facilitate studies of the mechanism underlying the PK-M2 to
PK-M1 isoform switch during terminal differentiation, we exam-
ined several established systems for cell differentiation in culture.
We found that proliferating mouse C2C12 myoblasts induced to
terminally differentiate into myotubes (15) switched protein and
mRNA isoform expression from almost exclusively PK-M2 to
predominantly PK-M1 (Fig. 2). Consistent with PK-M2 being
the predominant isoform in proliferating cells, and PK-M1 being
the predominant isoform in muscle (Fig. 1A), this switch in PK-M
isoform accompanied the morphological differentiation of the
C2C12 myoblasts into myotubes (Fig. 2A). Normalizing to total
PK-M protein expression, it is readily apparent that there was a
pronounced increase in PK-M1 upon differentiation, at the
expense of the PK-M2 isoform (Fig. 2B). Likewise, at the mRNA
level, the proportion of the M1 isoform changed from 5% to 55%
over a differentiation time course (Fig. 2C).
We also measured the protein levels of representative alterna-
tive splicing factors, including some known to have oncogenic
activities (3). In the C2C12 differentiation model, as well as in
mouse or human tissues and cancer-cell lines, we observed a
correlation between high levels of the alternative splicing factors
hnRNP A1/A2 and PTB, and reduced expression of the PK-M1
isoform (Fig. 2B, D, and E). In contrast, there was little or no
change in several other splicing factors, such as SF2/ASF and
Fig. 1. Protein and transcript expression patterns of pyruvate kinase M1/M2 isoforms in cells and tissues. (A) Total adult-mouse organ/tissue homogenates
were used for Western blotting with the indicated antibodies. rM1 and rM2: Flag-tagged purified recombinant human PK isoforms. (B) Total cell lysates of five
human cancer-cell lines were used for Western blotting with the indicated antibodies. (C) Primers annealing to exon 8 and exon 11, respectively, were used to
amplify mouse or human PK-M transcripts. The alternative exons that encode the distinctive segments of PK-M1 and PK-M2 are indicated in (black) and (gray),
respectively. To distinguish between PK-M1 (exon 9 included) and PK-M2 (exon 10 included) isoforms, the PCR products were cleaved with NcoI, PstI, or both.
There is an additional NcoI site (*) 11 bp away from the 3′ end of mouse exon 11. (D) Mouse organs were freshly dissected and perfused with saline. Total RNA
was analyzed by radioactive RT-PCR followed by digestion with NcoI (N), PstI (P), or both enzymes (NP), plus an uncut control (U). Numbered bands are as
follows: 1: Uncut M1 (502 bp); 2: uncut M2 (502 bp); 2*: M2 cleaved with NcoI in exon 11 (491 bp); 3: Pst1-cleavedM2 5’ fragment (286 bp); 4: NcoI-cleavedM1 5′
fragment (245 bp); 5: NcoI-cleaved M1 3’ fragment (240 bp); 6: PstI-cleaved M2 3’ fragment (216 bp); 7: PstIþ NcoI-cleaved M2 3’ fragment (205 bp). The %M1
was quantified from band 1 (M1) and bands 3 and 6 (M2) in each P lane. (E) RT-PCR and restriction digest analysis of total RNA from the indicated human cell
lines. The bands are numbered as for the mouse RT-PCR products, but the sizes are different because of the positions of the primers; the sizes are as follows: 1:
398 bp; 2: 398 bp; 3: 185 bp; 4: 144 bp; 5: 248 bp; 6: 213 bp. Note that the PK-M1 bands in the P and U lanes migrate slightly above the PK-M2 bands, which is also
the case for the mouse PK-M1 transcripts.








CUG-BP1 (Fig. 2B). U-118MG and A-172 cells, which expressed
detectable levels of PK-M1, both at mRNA and protein levels
(Fig. 1B, E), had less hnRNPA1/A2 and PTB compared to HeLa,
HEK293, and SK-N-BE cells, whereas SF2/ASF was expressed at
similar levels in these cell lines (Fig. 2D). Both hnRNPA/B and
PTB (also known as hnRNP I) protein family members are well
characterized splicing repressors, which led us to hypothesize that
these factors might be partly responsible for repressing the use of
exon 9 during prem-RNA splicing.
Blocking the 3′ Splice Site of Exon 10 Causes Abnormal Skipping of
Both Exons 9 and 10. To determine if exon 9 is actively repressed
in cancer-cell lines, or simply fails to compete effectively with
exon 10, we blocked the 3′ or 5′ splice sites of exon 10 using
2′-O-methyl, phosphorothioate antisense oligonucleotides com-
plementary to these regions (16) (Fig. 3A). The oligonucleotides
were transfected into HEK293 cells and the endogenous PK
mRNA isoforms were analyzed by radioactive RT-PCR (Fig. 3B).
As expected, use of exon 10 was partially inhibited by the
antisense oligonucleotides. However, in addition to increased
use of exon 9 (PK-M1 isoform), we observed an abnormal mRNA
arising from skipping of both mutually exclusive exons. These
results indicate that even with reduced use of exon 10, there is
residual repression of exon 9 use.
hnRNP Proteins Repress Exon 9 in a Gliobloastoma Cell Line. To
address whether specific hnRNP proteins are responsible for
repression of exon 9, we generated stable cell lines expressing
shRNAs directed against hnRNP A1, A2, or PTB (Fig. 4). We
chose A-172 glioblastoma cells for this analysis, both because they
already express some PK-M1 (Fig. 1B, E) and because they
tolerated simultaneous stable-knockdown of hnRNP A1 and
A2, in contrast to other cells we examined. We achieved ∼65%
knockdown of hnRNP A1 and ∼50% knockdown of hnRNP A2
(Fig. 4A). Although individual knockdown of these proteins—
which are closely related in structure and function (17)—had
little effect, the combined knockdown elicited a ∼6-fold increase
in PK-M1 protein (Fig. 4A) and ∼5-fold increase in PK-M1
mRNA (Fig. 4B).
PTB or PTBþ nPTB siRNA-knockdown in HeLa cells was
previously shown by quantitative 2D-gel proteomics to decrease
total PK-M expression (12). Although the PK-M1 and PK-M2
spots could not be resolved, RT-PCR revealed a ∼4-fold increase
in the PK-M1/M2 ratio (12). We stably expressed PTB shRNA in
A-172 cells and performed Western blotting and radioactive RT-
PCR analyses as above, and detected a ∼3-fold increase in PK-M1
protein and mRNA (Fig. 4C,D). Taken together, these results
suggest that hnRNP A1/A2 and PTB directly or indirectly med-
iate active repression of exon 9 in cancer cells.
Knockdown of Splicing Repressors Inhibits Lactate Production in a
Glioblastoma Cell Line. To test whether knockdown of hnRNP
A1/A2 or PTB, which results in an increase in the PK-M1/PK-
M2 protein ratio, is sufficient to affect cancer-cell metabolism,
we measured the extent of lactate production in stable-knock-
down versus control A-172 cells (Fig. 5). Remarkably, we ob-
Fig. 2. Expression of pyruvate-kinase isoforms and selected splicing factors
in cell lines and tissues. (A) Differentiation of mouse C2C12 myoblasts into
myotubes. The left field shows proliferating myoblasts, and the right field
shows cells after seven days in differentiationmedium, whenmost of the cells
have fused into myotubes. (B) Western blot of proliferating myoblasts versus
AraC-treated myotubes with the indicated antibodies against selected
splicing factors, β-catenin, total PK-M, and PK-M1 or PK-M2. (C) Radioactive
RT-PCR analysis of PK-M1 and PK-M2 expression in C2C12 cells over a differ-
entiation time course. Bands are numbered as in Fig. 1D. (D) Total cell lysates
of five human-tumor or transformed cell lines were used forWestern blotting
with the indicated specific antibodies. Tubulin was used as an internal control
for loading. HeLa (cervical carcinoma); HEK293 (transformed embryonic
kidney cells); SK-NB-E (neuroblastoma); U-118MG (glioma); A-172 (glioblasto-
ma). (E) Mouse tissues were analyzed as in Fig. 1A, with the indicated
antibodies.
Fig. 3. Exon 9 is partially rescued in HEK293 cells when exon 10 is blocked.
(A) Schematic representation of the strategy used to block exon 10 with 2′-O-
methyl antisense oligonucleotides. The two arrows above exon 10 denote the
oligonucleotides complementary to the 3′ splice site and 5′ splice site regions.
(B) Radioactive RT-PCR assay to measure PK-M1/PK-M2 levels after blocking
each of the exon 10 splice sites with antisense oligonucleotides. An abnormal
isoform arising from skipping of both exons 9 and 10 is indicated. (C) Quan-
titation of multiple experiments. (Error bars show s.d.; n ¼ 3; p-values:
¼0.007; ¼0.005; ¼0.004; ¼0.001; Student’s paired t-test).
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served a >2-fold decrease in lactate production upon combined
knockdown of hnRNP A1/A2, and a ∼1.5-fold reduction upon
knockdown of PTB.
Discussion
We have demonstrated that downregulation of the splicing
repressors hnRNP A1/A2 and PTB relieves repression of
PK-M exon 9 inclusion, resulting in higher levels of PK-M1.
Both types of hnRNP proteins have been implicated in cancer
(2, 3, 18), consistent with their ability to promote expression
of the protumorigenic PK-M2 isoform. hnRNP A1 and A2 are
closely related proteins encoded by two separate genes
(HNRNPA1 and HNRNPA2B1), which express additional minor
isoforms (19); they are splicing repressors that typically, but not
always, recognize exonic splicing silencer elements, and once
bound to these elements they can spread along the RNA through
cooperative interactions and interfere with the binding of
spliceosomal components or activator proteins (20). PTB
(hnRNP I) is also an abundant RNA-binding protein that binds
to polypyrimidine tracts, such as those present at or upstream of
Fig. 4. Repression of exon 9 by hnRNP proteins. (A) A-172 glioblastoma cells were transduced with retroviruses expressing hnRNPA1 and hnRNP A2 shRNAs.
Total lysates were analyzed by Western blotting with the indicated antibodies. The histogram on the right shows the quantitation of multiple experiments by
infrared-imaging (n ¼ 4; error bars show s.d.; p ¼ 0.02 (M1); p ¼ 0.005 (M2); p ¼ 0.05 (A1); p ¼ 0.01 (A2); Student’s paired t-test) (B) Analysis of PK -MRNA
transcripts from the cells in (A) using radioactive RT-PCR and NcoI or PstI digestion. Bands are numbered as in Fig. 1E. The histogram on the right shows the
quantitation from several experiments (error bars show s.d.; n ¼ 4; p ¼ 10−4 for the A1/A2 double-knockdown; Student’s paired t-test) (C) and (D) As in (A) and
(B) but using shRNAs against PTB (hnRNP I). (C) The * on each side indicates the band corresponding to PK-M1. The histogram on the right shows the quantita-
tion (n ¼ 4; error bars show s.d.; p ¼ 0.03 (M1); p ¼ 0.01(M2); p ¼ 0.03 (PTB); Student’s paired t-test). (D) The histogram on the right shows the quantitation



















EV A1/A2 KD PTB KD
Fig. 5. Effect of splicing-repressor knockdown on metabolism of glioblasto-
ma cells. Lactate production was measured in A-172 glioblastoma cells trans-
ducedwith empty vector or with combined shRNAs against hnRNPA1 and A2,
or against PTB. Error bars show s.d.; n ¼ 12 for EV control, and n ¼ 6 for A1/A2
(p ¼ 0.0034) and PTB (p ¼ 0.014) knockdowns; Student’s paired t-test.








3′ splice sites, and it can regulate alternative splicing by creating a
zone of silencing (21).
Previous analysis of PK-M splicing using a minigene suggested
that inclusion of exon 10 is the default splicing pattern in prolif-
erating cells (14). This is consistent with our observation that
blocking either of the splice sites of exon 10 by means of antisense
oligonucleotides leads to simultaneous skipping of both exons 9
and 10, rather than to efficient derepression of exon 9. We have
shown that hnRNPA1/A2 and PTB are responsible for, or con-
tribute to the repression of exon 9 in cells that express PK-M2.
Although preferred motifs recognized by these repressors are
known, we have not determined yet whether hnRNP A1/A2
and PTB regulate PK-M alternative splicing directly, and if so,
where the relevant binding sites are located. However, two recent
studies reported that PTB can be crosslinked in cells to several
regions in intron 8 (22) and hnRNP A1 can bind in vitro to an
RNA fragment encompassing the 5′ splice site of intron 9
(23). Further studies of cis-acting elements within and flanking
both exon 9 and exon 10 will be necessary to uncover how indi-
vidual cells achieve predominant or exclusive expression of only
one of the two isoforms.
Considering that downregulation of hnRNP A1/A2 or PTB
achieved only a three to fivefold increase over the low basal level
of exon 9 inclusion, accompanied by a modest increase in PK-M1
protein with the persistence of PK-M2 protein, additional factors
likely contribute to the usually tight control of PK-M alternative
splicing. As in other instances of regulated alternative splicing
[reviewed in (24)], combinatorial control by numerous RNA-
binding proteins is likely operative for the PK-M gene.
The effects we observed on lactate production following com-
bined knockdown of hnRNP A1/A2 are likely attributable to
more than just the switch in PK-M isoform expression. hnRNP
A1/A2 knockdown resulted in some PK-M1 protein expression,
although cells continued to express appreciable amounts of
PK-M2. A nearly complete switch of PK-M2 to PK-M1 using
shRNA knockdown and isoform-specific rescue constructs re-
sulted in at most a 30% decrease in lactate production (1). Thus,
the >2-fold reduction in lactate production we observed following
combined hnRNPA1þA2 knockdown probably reflects changes
in alternative splicing that presumably occur in addition to those
involving PK-M1/M2.
Aside from PK-M, additional genes important for cancer-cell
metabolism are alternatively spliced. For instance, the bifunc-
tional enzyme phosphofructokinase/bisphophatase B3 gene
(PFKFB3) is a key regulator of glycolysis with preferential expres-
sion in cancer cells (25, 26). The kinase activity of this gene
product generates fructose 2,6 bisphosphate (F2,6BP), which
activates phosphofructokinase-1, a rate-limiting and regulatory
control point of glycolysis, and indirectly leads to PK-M2 activa-
tion. In addition, HIF-1α and oncoproteins such as Ras activate
PFKFB3, leading to increased F2,6BP in tumors (26). Multiple
alternatively spliced isoforms of PFKFB3 exist, though their
distinctive properties have not been characterized. There is
cross-talk between cell-energy sensing and pyruvate-kinase
regulation of this enzyme, suggesting that regulation of splicing
to generate specific isoforms may be part of a larger metabolic
program to promote proliferative metabolism (27). We speculate
that hnRNP A1/A2 might modulate the expression of other
alternatively spliced metabolic genes, in addition to PK-M, that
collectively account for the large decrease in lactate production
following double knockdown of hnRNP A1 and A2.
Materials and Methods
Cells and Transfections. HeLa, HEK293, U-118MG, A-172, SK-N-BE, and C2C12
cells were grown in DMEM, supplemented with 10% (v/v) FBS, penicillin, and
streptomycin. To induce differentiation, near-confluent C2C12 cultures were
washed 3X with PBS and maintained for 7 d in medium containing 2% (v/v)
horse serum, penicillin, and streptomycin. To select for a more homogenous
differentiated culture, myotubes were treated for 4 d with 25 μM cytosine
β-D-arabinofuranoside hydrochloride (AraC) (Sigma) beginning on day 7
after inducing differentiation. To generate stable transductant pools,
A-172 cells were infected with LMP-puro or LMP-hygro retroviral vectors
(3). The medium was replaced 24 h after infection, and starting 1 d later, in-
fected cells were selected with puromycin (2 μgmL−1) for 3 d, or hygromycin
(200 μgmL−1) for 7 d. In the case of double infections, cells were treated with
hygromycin for 7 d after selection with puromycin for 3 d. Short hairpin RNA






Immunoblotting. Cells were lysed in SDS and total protein concentration was
measured. 30 μg of total protein from each lysate was separated by SDS-PAGE
and transferred onto a nitrocellulose membrane. This was followed by
blocking with 5% milk in Tris-buffered saline with Tween, probing with
the indicated antibodies, and quantitation using an Odyssey infrared-
imaging system (LI-COR Biosciences). Primary antibodies were: β-catenin (Ab-
cam rAb 6302, 1∶4; 000); tubulin (Genscript rAb, 1∶5; 000); SF2/ASF (mAb AK96
culture supernatant, 1∶100 (28)); hnRNP A1 (Abcam mAb 4B10, 1∶1; 000 or
mAb UP1-55 culture supernatant (29)); hnRNP A2 (Abcam mAb DP3,
1∶1; 000); hnRNP A1/A2 (A1/UP1-62 culture supernatant, 1∶20 (29)); PTB
(mAb SH54 culture supernatant, 1∶100 (30) or Abcam rAb83897, 1∶1; 000);
CUG-BP1 (Abcam mAb 3B1, 1∶500); PK-M2 (rabbit, 1∶500) and PK-M1 (rabbit,
1∶2; 000) (1); total PK-M (Abcam gAb6191, 1∶1; 000). Secondary antibodies
were IRdye 800 or 680 anti-rabbit, anti-mouse, or anti-goat (LI-COR
Biosciences, 1∶10;000).
RT-PCR Assays. 2 μg of total RNA was extracted from freshly dissected, saline-
perfused mouse tissues, and from cell lines, using Trizol reagent (Invitrogen).
Contaminating DNA was removed by treatment with DNase I (Promega).
Reverse transcription was carried out using ImPromp-II reverse transcriptase
(Promega). Semiquantitative PCR using AmpliTaq polymerase (Applied
Biosystems) was performed by including [α-32P]-dCTP in the reactions. The
mouse- and human-specific primer sets anneal to exons 8 and 11, and their
sequences are as follows: hPKMF: 5′-AGAAACAGCCAAAGGGGACT-3′;
hPKMR: 5′-CATTCATGGCAAAGTTCACC-3′ and mPKMF: 5′-ATGCTGGAGAG-
CATGATCAAGAAGCCACGC-3′; mPKMR: 5′-CAACATCCATGGCCAAGTT-3′.
After 22 amplification cycles, the reactions were separated into four aliquots
for digestion with NcoI, PstI (New England Biolabs), both, or neither. The
products were analyzed on a 5% native polyacrylamide gel, visualized by
autoradiography, and quantitated on a FUJIFILM FLA-5100 phosphoirmager
(Fuji Medical Systems) using Multi Gauge software Version 2.3 (Fujifilm). The
%M1 mRNA was calculated using the GC-content-normalized intensities of
the top undigested band (M1) and the bottom two digested bands (M2)
in the PstI-digest lanes.
Antisense Oligonucleotides. 2′-O-methyl phosphorothioate oligonucleotides
were purchased from TriLink Biotechnologies, and purity was confirmed
by gel electrophoresis. 3′ splice site antisense oligonucleotide: CGGGCAATC-
TAGGGGAGCAAC; 5′ splice site antisense oligonucleotide: CCGCCTCCT-
ACCTGCCAGAC. HEK293 cells were plated at 50,000 cells per well in 6-well
plates in DMEM supplemented with 10% fetal calf serum, 500 units∕mL pe-
nicillin, and 0.1 mg∕mL streptomycin. After allowing cells to adhere, they
were transfected with 500 nM oligonucleotide using Lipofectamine 2000
(Invitrogen). After 4 h at 37 °C, the transfecting mixture was replaced with
fresh mediumwith serum. After 48 hr, the cells were washed three times with
PBS, trypsinized, counted, and extracted RNAwas analyzed by radioactive RT-
PCR as described above.
Lactate Assays. Lactate production was measured using a fluorescence-based
assay kit (BioVision). Fresh medium was added to a 12-well plate of
subconfluent cells and aliquots of media from each well were assessed
30 min later for the amount of lactate present. The cells were counted with
a hemocytometer.
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